Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

SGLT2 inhibitors and new-onset chronic kidney disease in patients with diabetes

SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan.

Diabetes research and clinical practice

Citation & Authors

Diabetes Res Clin Pract. 2026;236:113267.

Fu-Shun Yen; James Cheng-Chung Wei; Yao-Min Hung; Jia-Sin Liu; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance study matched 11,617 pairs of patients with diabetes and no CKD at baseline. SGLT2 inhibitor use was associated with lower risks of incident CKD (aHR 0.86; 95% CI 0.83–0.89), macroalbuminuria, acute kidney injury, cardiovascular events, and death. Although the dialysis estimate was lower, its CI crossed 1 (0.46; 0.20–1.06) and should not be described as a statistically significant reduction.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗